VIA
GLUE icon

Virtus Investment Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History

Virtus Investment Advisers’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
16,718
+408
+3% +$7.8K 0.08% 294
2025
Q4 		$256K Sell
16,310
-6,818
-29% -$91.9K 0.07% 318
2025
Q3 		$171K Buy
23,128
+4,016
+21% +$21.3K 0.05% 337
2025
Q2 		$86.2K Sell
19,112
-1,961
-9% -$8.75K 0.03% 399
2025
Q1 		$97.8K Buy
+21,073
New +$129K 0.03% 425
2023
Q1 		– Sell
-12,638
Closed -$96.2K – 301
2022
Q4 		$96.2K Hold
12,638
– – 0.06% 274
2022
Q3 		$103K Buy
+12,638
New +$116K 0.05% 292

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Virtus Investment Advisers's GLUE Position: Q1 2026 in Review

Virtus Investment Advisers increased its Monte Rosa Therapeutics (GLUE) stake by 2.5% in Q1 2026, buying an estimated $7.8K and bringing the position to 16,718 shares worth $275K. The position accounts for 0.08% of the portfolio, ranked #294.

Virtus Investment Advisers first reported a position in GLUE in Q3 2022 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Virtus Investment Advisers held 16,718 shares of Monte Rosa Therapeutics worth $275K as of Q1 2026.
  • Virtus Investment Advisers bought 408 Monte Rosa Therapeutics shares in Q1 2026, an estimated $7.8K.
  • Monte Rosa Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #294 holding.
  • Virtus Investment Advisers first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.